A Phase 2 Trial of Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation
Phase of Trial: Phase II
Latest Information Update: 21 May 2019
At a glance
- Drugs Dabrafenib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 17 May 2019 Status changed from active, no longer recruiting to completed.
- 04 Jun 2018 Planned End Date changed from 1 Sep 2018 to 1 Sep 2019.
- 04 Jun 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Sep 2019.